Alkermes targets get a post-earnings lift from the Street

Alkermes reported earnings on November 3 and walked into the week with a question traders often face in biotech: does the stock's short interest, now elevated after a month-long build, reflect genuine scepticism or positioning that the bulls can pressure? With analysts moving targets higher the morning after the print, the note this week is really about whether the Street's post-earnings conviction lines up with how the lending market is positioned.

The short interest picture is the most interesting tension in the data. At just under 12% of free float, short positioning has climbed roughly 19% over the past month, a meaningful build that leaves nearly 19.5 million shares sold short. The week itself saw a modest easing, down about 2%, but that follows a sharp step-up in October. The lending market, however, tells a different story about urgency. Availability is around 640%, meaning there are more than six shares available to borrow for every one already borrowed, well above the 52-week tightest point of 329%. Cost to borrow has risen about 86% over the past month in percentage terms but remains low in absolute terms at 0.63%. The borrow market is simply not tight. Options positioning reinforces that neutrality: the put/call ratio is 0.87, barely a third of a standard deviation above its 20-day average, and far off the defensive extremes seen in late September when the ratio was above 1.1. Taken together, the shorts are there in size but are not fighting the tape in the lending market.

The Street moved decisively in Alkermes' direction the morning after the print. Wells Fargo raised its target to $68 from $65 while keeping Overweight, and RBC Capital nudged to $57 from $56 at Outperform, both filed November 4. HC Wainwright, which carried a Neutral, lifted its target more sharply, to $50 from $43. The mean target across the 12 buy-rated analysts is $56.21, against a close of $45.69, implying roughly 23% return potential from current levels. The bull case centres on the neuroscience franchise, Lumryz, Lybalvi, Aristada and Vivitrol, plus the orexin pipeline, where Phase 1b ADHD data and hypersomnia results have given credibility to what was previously pipeline optionality. Forward EPS estimates rank in the 99th percentile for year-on-year increase, and 30-day EPS momentum scores 75. The bear case is straightforward: the orexin program still lacks large-study validation, Medicaid exposure adds policy risk, and significant ongoing R&D spend raises the chance of dilutive financing if the pipeline disappoints. The EV/EBITDA of about 16 times has compressed roughly 2.2 turns over the past 30 days, partly reflecting the higher earnings base as the stock moved.

Institutional ownership provides a stable foundation. BlackRock is the largest holder at roughly 17.4% of shares, and State Street added nearly 984,000 shares in the third quarter. T. Rowe Price was the most active buyer in Q3, adding about 2.3 million shares to reach 4.7% of the company. No 13D activist is present on the register. All filings on record are passive Schedule 13G disclosures. The most recent insider activity is mechanical rather than conviction-driven: the CLO sold 2,035 shares on November 3 under a pre-arranged 10b5-1 plan, and the CFO's October activity was a compensation-related option exercise paired with a tax-withholding sale. Net insider flow over the past 90 days is modestly negative at around negative $1.1 million, but the transactions are almost entirely plan-driven, limiting their signal value.

The alt data layer flags that retail attention, proxied by Wikipedia page views, is running roughly two standard deviations below the company's own 90-day average, a low-attention reading that tends to accompany periods of institutional rather than retail price discovery. Medicaid unit reimbursements were up 13% year on year in Q1 2026, a positive read on demand for the core commercial products, though no dataset in the ORTEX alt data library has been measured as a leading indicator for Alkermes' reported financials. The next earnings event is pencilled in for February 25, 2027, leaving 113 days for the pipeline narrative and orexin data to do the work.

The setup heading into the next few weeks is therefore a tension between elevated but non-squeezable short interest and an analyst community that just moved its targets higher after a print. What to watch is whether the 12% short position begins to cover in a sustained way as the gap between the $45.69 close and the $56-to-$68 analyst target range draws more attention, or whether bears press the thesis that orexin validation remains the primary risk and hold their ground until larger clinical data arrive.